Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says

Sarepta Therapeutics' (SRPT) regulatory review of its Elevidys therapy for Duchenne muscular dystrophy is advancing faster than anticipated, Morgan Stanley said in a report emailed Thursday. "Overall,

MT Newswires03:42

Sarepta Elevidys Accelerated Approval Criticized by ICER Exec

Seeking Alpha03:36

Sarepta Therapeutics Price Target Maintained With a $128.00/Share by Cantor Fitzgerald

Sarepta Therapeutics Price Target Maintained With a $128.00/Share by Cantor Fitzgerald

Dow Jones00:23

Cantor Fitzgerald, Inc.: Reiterates the Sarepta Therapeutics (SRPT.US) rating and adjusted from neutral to neutral, with a target price of $128.00.

Cantor Fitzgerald, Inc.: Reiterates the Sarepta Therapeutics (SRPT.US) rating and adjusted from neutral to neutral, with a target price of $128.00.

Zhitong Finance00:20

UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating

Sarepta Therapeutics (SRPT) has an average outperform rating and a price target range of $128 to $224, according to analysts polled by Capital IQ. Price: 134.86, Change: +3.96, Percent Change: +3.03

MT NewswiresMay 2 23:30

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh

Simply Wall StMay 2 22:37